Unlocking Immuno-Oncology by Unraveling the Immune Response

January 26 , 2016
1 pm to 2 pm EST


Sponsored by
Nodality logo

Webinar Description:

Immuno-Oncology therapies are revolutionizing drug development and patient care in oncology. It holds the promise of transforming the management of oncology patients and improving the lives of millions. However, a deeper understanding of the interplay between the tumor and the immune system is required to address the challenges in selecting the best treatment of a given patient, informing on potential drug combination approaches and anticipating immune-related toxicities associated with these new Immuno-Oncology therapies. The webinar is a discussion on the opportunity these new therapies present, their challenges and the approaches being utilized to address those challenges and maximize their potential for improved patient care.

Learning Objectives:

  • Immuno-Oncology market dynamics and needs
  • The challenges facing I-O drug developers and health care providers
  • Insight into technological approaches and strategies to identify and select biomarkers
  • Benefits and limitations of current approaches to drug development and biomarker selection
  • Unique value of Functional Proteomics to optimize the impact and effectiveness of I-O therapeutics


Dr. Rachael Hawtin, Ph.D.

VP Research


Dr. Rachael Hawtin has over 18 years of experience in drug development, encompassing small molecules and biologics for oncology and autoimmune indications. She has held leadership positions in drug development programs spanning discovery biology through to clinical development in the context of both international companies and small biotechnology organizations. Prior to joining Nodality, she held various positions at Sunesis Pharmaceuticals, progressing to the lead role in the translational science component of two clinical stage programs. Rachael previously led the small molecule target discovery program at Chiron Corporation. Additionally, she held progressively responsible positions at Sugen Inc., where she served as leader of a protein expression technology group, and as leader of a small molecule oncology drug development program. Rachael completed her B.Sc. at the University of Edinburgh, Scotland, and her Ph.D. at the Institute of Virology and Environmental Microbiology (IVEM) in Oxford, England.

Dr. Bradford A. Young, Ph.D., MBA

VP, Business Development


Dr. Bradford A. Young is an accomplished life sciences executive with over 20 years of experience developing markets, designing and launching innovative products, creating strategic partnerships and leading commercial programs. His deep business and technical background has enabled him to successfully capitalize on unmet medical needs and market opportunities. As Head of Business Development, Dr. Young is leading Nodality’s sales and marketing efforts. Dr. Young’s leadership experience prior to Nodality included CEO of the life sciences start-up company AddisonField, Executive Director of the SFY Foundation, a cancer charity and Director of Market and Business Development for Quest Diagnostics (formerly Celera). Dr. Young is also actively involved in the industry as a mentor for the LeanLaunch Pad, a NSF I-Corps™ program and as a selection committee member for SPADA, the Stanford Predictives and Diagnostics Accelerator program. Dr. Young earned his doctorate from the University of Maryland, School of Medicine and his MBA from the University of California, Berkeley, Haas School of Business.

Cost: No cost!

Schedule conflict? Register and you'll receive a copy of the recording!

>> Register Today

By Series:
By Region: